Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016
A Systematic Analysis for the Global Burden of Disease Study

Global Burden of Disease Cancer Collaboration

**Importance** The increasing burden due to cancer and other noncommunicable diseases poses a threat to human development, which has resulted in global political commitments reflected in the Sustainable Development Goals as well as the World Health Organization (WHO) Global Action Plan on Non-Communicable Diseases. To determine if these commitments have resulted in improved cancer control, quantitative assessments of the cancer burden are required.

**Objective** To assess the burden for 29 cancer groups over time to provide a framework for policy discussion, resource allocation, and research focus.

**Evidence Review** Cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs) were evaluated for 195 countries and territories by age and sex using the Global Burden of Disease study estimation methods. Levels and trends were analyzed over time, as well as by the Sociodemographic Index (SDI). Changes in incident cases were categorized by changes due to epidemiological vs demographic transition.

**Findings** In 2016, there were 17.2 million cancer cases worldwide and 8.9 million deaths. Cancer cases increased by 28% between 2006 and 2016. The smallest increase was seen in high SDI countries. Globally, population aging contributed 17%; population growth, 12%; and changes in age-specific rates, −1% to this change. The most common incident cancer globally for men was prostate cancer (1.4 million cases). The leading cause of cancer deaths and DALYs was tracheal, bronchus, and lung cancer (1.2 million deaths and 25.4 million DALYs). For women, the most common incident cancer and the leading cause of cancer deaths and DALYs was breast cancer (1.7 million incident cases, 535,000 deaths, and 14.9 million DALYs). In 2016, cancer caused 213.2 million DALYs globally for both sexes combined. Between 2006 and 2016, the average annual age-standardized incidence rates for all cancers combined increased in 130 of 195 countries or territories, and the average annual age-standardized death rates decreased within that timeframe in 143 of 195 countries or territories.

**Conclusions and Relevance** Large disparities exist between countries in cancer incidence, deaths, and associated disability. Scaling up cancer prevention and ensuring universal access to cancer care are required for health equity and to fulfill the global commitments for noncommunicable disease and cancer control.
The year 2017 marked another milestone in the global commitment to control cancer. In May 2017, a new cancer resolution was adopted during the 70th World Health Assembly, suggesting that focused efforts are urgently needed to achieve the goals for the 2011 Political Declaration on the Prevention and Control of NCDs (noncommunicable diseases) (25% reduction in premature mortality from NCDs) as well as for the third Sustainable Development Goal (“by 2030 reduce by one-third premature mortality from non-communicable diseases [NCDs] through prevention and treatment, and promote mental health and wellbeing”). Even with increased awareness of the threat that NCDs pose to human development, progress on NCD control has been slow in most countries. This is despite the fact that we are now entering a time when reductions in mortality would be expected if the 2011 declaration had led to policy changes. Compared with other health threats like human immunodeficiency virus, tuberculosis, or malaria, cancer represents many drastically different diseases that require unique approaches for prevention, diagnosis, and treatment. Thus far, few countries have been able to overcome this challenge. To achieve equitable cancer control over the next decade, continued commitment from all stakeholders, appropriate funding, and effective approaches are necessary. The Global Burden of Disease (GBD) study provides data to direct efforts where they are most needed and to identify progress and obstacles in cancer control.

In this study, we describe the burden of cancer using results from the GBD 2016 study for 29 cancer groups by sex, age, and over time for 195 countries or territories.

Methods

Methods have remained similar to the GBD 2015 study. As in each prior GBD study, the entire time series was reestimated, and results presented in this study supersede prior GBD studies. All cancers as defined in the International Classification of Diseases (ICD) were categorized into 29 cancer groups. Changes since GBD 2015 include new data additions, the addition of “other leukemia” as a cause, changes in the mortality-to-incidence ratio (MIR) estimation, as well as reporting estimates for nonmelanoma skin cancer (NMSC). For GBD 2016, we estimated national disease burden for 195 countries and territories. Descriptions of the methods can be found in the GBD 2016 publications as well as in the eAppendix, eFigures, and eTables in the Supplement. The GBD 2016 study is compliant with GATHER guidelines (eTable 1 in the Supplement). All rates are reported per 100 000 person-years. The GBD world population standard was used for the calculation of age-standardized rates. We report 95% uncertainty intervals (UIs) for all estimates.

Estimation Framework

The GBD estimation process starts with cancer mortality. Data sources for cancer mortality include vital registration system (83% of data), cancer registry (14.4% of data), and verbal autopsy data (3% of data) (eTable 2 in the Supplement). Since cancer registries often exist in locations without cancer mortal-
Table. 2016 Global Incidence and Deaths for All Cancers and 29 Specified Cancer Groupsa

| Cancer Typeb | Incident Cases, Thousandsc | ASIRc | Deaths, Thousandsc | ASIRc |
|-------------|---------------------------|-------|-------------------|-------|
| Total Male  | 17,228 (16,713-17,803)    | 206.8 (206.8-222.0) | 176 (169-183) | 171.9 (167.9-175.7) |
| Total Female | 228 (224-244)             | 4.0 (4.0-4.1) | 118 (112-124) | 95 (90-99) |
| Male         | 9,427 (9,128-9,794)       | 2.0 (1.9-2.1) | 64 (61-67) | 1.4 (1.3-1.5) |
| Female       | 148 (145-151)             | 0.7 (0.6-0.7) | 47 (44-50) | 0.4 (0.4-0.5) |
| Lip and oral cavity | 382 (371-392) | 7.1 (6.8-7.4) | 4.0 (4.0-4.1) | 3.7 (3.5-3.8) |
| Nasopharynx  | 96 (91-101)               | 2.0 (1.9-2.1) | 64 (61-67) | 1.4 (1.3-1.5) |
| Other pharynx| 170 (159-176)             | 3.8 (3.5-4.0) | 119 (109-125) | 2.6 (2.4-2.8) |
| Esophageal   | 443 (433-456)             | 10.2 (10.0-10.6) | 415 (404-427) | 9.9 (9.6-10.3) |
| Stomach      | 1157 (1134-1180)          | 25.0 (24.3-25.8) | 834 (814-855) | 17.9 (17.3-18.4) |
| Colon and rectum | 1716 (1658-1795) | 31.6 (30.4-33.2) | 830 (797-860) | 35.1 (33.9-36.3) |
| Liver        | 1008 (953-1042)           | 22.3 (21.0-23.1) | 829 (796-858) | 18.3 (17.5-19.0) |
| Gallbladder | 202 (200-205)             | 2.6 (2.1-2.9) | 162 (157-168) | 2.3 (1.9-2.6) |
| Pancreatic   | 418 (406-425)             | 7.3 (7.0-7.4) | 405 (394-416) | 7.1 (6.9-7.3) |
| Larynx       | 187 (184-191)             | 5.0 (4.9-5.1) | 111 (108-115) | 0.6 (0.5-0.7) |
| Tracheal, bronchus, and lung | 2008 (1958-2055) | 44.9 (43.6-46.1) | 1707 (1659-1753) | 39.1 (37.7-40.4) |
| Malignant skin melanoma | 282 (243-314) | 4.8 (4.3-5.1) | 62 (54-67) | 1.1 (1.0-1.2) |
| Nonmelanoma skin cancer | 1521 (1109-2008) | 29.1 (21.2-40.0) | 53 (51-55) | 0.5 (0.5-0.5) |
| Nonmelanoma skin cancer (SCC) | 635 (386-922) | 14.3 (8.7-22.1) | 53 (51-55) | 1.3 (1.2-1.3) |
| Nonmelanoma skin cancer (BCC) | 886 (574-1262) | 14.9 (9.6-21.5) | NA | 0.5 (0.5-0.5) |
| Breast | 1702 (1629-1801) | 0.6 (0.5-0.7) | 546 (517-582) | 0.3 (0.2-0.4) |
| Cervical | 511 (414-542) | 2.1 (1.0-1.1) | 247 (204-263) | 0.7 (0.6-7.7) |
| Uterine | 417 (401-442) | 11.4 (10.9-12.0) | 88 (83-92) | 2.4 (2.3-2.6) |
| Ovarian | 254 (242-260) | 6.9 (6.6-7.1) | 165 (157-173) | 4.5 (4.3-4.7) |
| Prostate | 1436 (1293-1619) | 49.9 (45.0-56.1) | 381 (321-413) | 14.9 (12.7-16.2) |
| Testicular | 67 (64-70) | 1.8 (1.7-1.8) | 9 (8-9) | 0.2 (0.2-0.3) |
| Kidney | 342 (331-350) | 6.5 (6.3-6.7) | 132 (127-136) | 2.9 (2.8-3.0) |
| Bladder | 437 (427-448) | 11.5 (11.2-11.8) | 186 (180-192) | 5.1 (4.9-5.3) |
| Brain and nervous system | 330 (299-349) | 5.1 (4.4-5.5) | 227 (205-241) | 3.8 (3.3-4.1) |
| Thyroid | 238 (229-253) | 2.2 (2.1-2.3) | 43 (41-45) | 0.6 (0.5-0.6) |
| Mesothelioma | 35 (33-36) | 0.8 (0.7-0.8) | 30 (28-32) | 0.7 (0.7-0.8) |
| Hodgkin lymphoma | 73 (66-82) | 1.2 (1.1-1.5) | 29 (25-34) | 0.5 (0.5-0.7) |
| Non-Hodgkin lymphoma | 461 (428-482) | 8.1 (7.3-8.9) | 240 (221-248) | 4.5 (4.0-4.7) |
| Multiple myeloma | 139 (121-155) | 2.4 (2.0-2.8) | 98 (87-110) | 1.7 (1.4-2.0) |

(continued)
### Table. 2016 Global Incidence and Deaths for All Cancers and 29 Specified Cancer Groups (continued)

| Cancer Type            | Total Male | Female | Total Male | Female | Male | Female | Male | Female | Total Male | Female | Male | Female | Male | Female |
|------------------------|------------|--------|------------|--------|------|--------|------|--------|------------|--------|------|--------|------|--------|
| Acute lymphoid leukemia | 76 (66-80) | 44 (38-47) | 32 (25-35) | 2.0 (1.9-2.3) | 1.2 (1.1-1.3) | 12 (11-13) | 7 (6-8) | 4 (3-5) | 31 (28-34) | 21 (19-22) | 15 (13-16) | 10 (8-11) | 6 (5-7) | 4 (3-5) |
| Chronic lymphoid leukemia | 105 (98-113) | 61 (56-68) | 45 (40-48) | 2.7 (2.4-3.0) | 1.7 (1.5-1.9) | 21 (18-23) | 13 (11-14) | 8 (7-9) | 35 (33-40) | 21 (18-21) | 15 (13-16) | 10 (9-11) | 6 (5-7) | 4 (3-5) |
| Acute myeloid leukemia | 103 (91-116) | 61 (56-68) | 46 (40-48) | 2.7 (2.4-3.0) | 1.7 (1.5-1.9) | 21 (18-23) | 13 (11-14) | 8 (7-9) | 35 (33-40) | 21 (18-21) | 15 (13-16) | 10 (9-11) | 6 (5-7) | 4 (3-5) |
| Chronic myeloid leukemia | 32 (28-34) | 19 (17-20) | 14 (12-15) | 0.6 (0.5-0.6) | 0.4 (0.3-0.5) | 12 (11-13) | 6 (5-7) | 3 (2-4) | 15 (13-16) | 9 (8-10) | 5 (4-6) | 3 (2-4) | 2 (2-3) |
| Other leukemia | 150 (127-167) | 87 (73-99) | 63 (53-70) | 2.3 (2.2-2.4) | 1.7 (1.5-1.9) | 21 (18-23) | 13 (11-14) | 8 (7-9) | 35 (33-40) | 21 (18-21) | 15 (13-16) | 10 (9-11) | 6 (5-7) | 4 (3-5) |
| Other neoplasms | 750 (682-772) | 439 (389-471) | 311 (256-362) | 12.1 (11.7-12.5) | 9.4 (9.0-9.9) | 236 (205-266) | 154 (138-172) | 80 (70-91) | 47 (40-53) | 267 (241-282) | 214 (190-235) | 115 (103-125) | 76 (68-84) | 50 (44-56) |

Abbreviations: ASIR, age-standardized incidence rate per 100 000 person-years; NA, not applicable; SCC, squamous cell carcinoma; UI, uncertainty interval.

1. Data reported in number or rate (95% UI).
2. Incidence data (per 100 000 person-years) for all cancers and causes of cancer deaths were other neoplasms (see eTables 4 and 5 in the Supplement for ICD codes included in “other neoplasms”), brain and nervous system cancers, and acute lymphoid leukemia (Figure 1 and Figure 2). For adolescents and young adults (age 20-39 years) the most common cancers globally were breast cancer, cervical cancer, and other neoplasms. The main causes of cancer deaths for this age group were other neoplasms, brain and nervous system cancers, and non-Hodgkin lymphoma. For the population older than 39 years, the cancers contributing the most incident cases were TBL, breast, prostate, and colorectal cancer, while the main contributors to cancer deaths were TBL, colorectal, and stomach cancer.

Between 2006 and 2016, the average annual age-standardized incidence rates (AAAsIRs) for all cancers combined increased in 130 of 195 countries (Figure 3). In contrast, the average annual age-standardized death rates (AAASDRs) for all cancers combined decreased within that timeframe in 143 of 195 countries (Figure 4). Countries with an increase in AAASDR were largely located on the African continent and Middle East. Between 2006 and 2016 the AAASDR decreased in all SDI quintiles except for the low SDI quintile (eFigure 5 in the Supplement). The AAASDR decreased for most cancers in the high, and high-middle SDI quintiles, whereas the changes in AAASDR were more heterogeneous for the other SDI quintiles (eFigures 5-14 in the Supplement).

Incidence cases for both sexes combined increased in all SDI quintiles between 2006 and 2016 for nearly all cancers (eTable 14 in the Supplement and Web Table 1; http://ghdx.healthdata.org/node/350478). The largest increase in cancer incidence cases between 2006 and 2016 occurred in middle SDI countries, with a 38% increase, of which changing age structure contributed 25%; population growth, 7%; and changing age-specific incidence rates, 6%. The drivers behind increasing cancer incidence differed substantially by SDI. Whereas in the lowest SDI quintile, population growth was the major contributor to the increase in total cancer incidence, in low-middle SDI countries, population growth and aging contributed almost equally (16.6% and 15.3%, respectively), and in high-middle, and high-income countries, increased incidence was mainly driven by population aging (eTable 14 in the Supplement).
Global Top 10 Cancers in 2016
The global top 10 cancers were ranked by the highest number of incident cases, excluding “other neoplasms” (Figure 5).

1. Tracheal, Bronchus, and Lung Cancer
In 2016, there were 2.0 million (95% UI, 2.0-2.1 million) incident cases of TBL cancer and 1.7 million (95% UI, 1.7-1.8 million) deaths; TBL cancer caused 36.4 million (95% UI, 35.4-37.5 million) DALYs in 2016, of which 99% came from YLLs and 1% from YLDs (eTable 15 and eFigure 4 in the Supplement). Men were more likely to develop TBL cancer over a lifetime than women (1 in 18 men, 1 in 46 women) (eTable 16 in the Supplement). The odds were the highest in high SDI countries (1 in 14 men, 1 in 26 women). In low SDI countries, the odds were substantially lower (1 in 75 men, 1 in 172 women); TBL cancer was the leading cause of cancer globally and in high-middle and middle SDI countries (Figure 5). It was the most common cause of cancer deaths by absolute cases globally as well as in all SDI quintiles, except for the low SDI quintile, where TBL cancer ranked seventh (Figure 6). For men, TBL cancer was the most common incident cancer in 42 countries and the most common cause for cancer deaths in 108 countries (eFigures 17 and 19 in the Supplement). For women, TBL cancer was the most common incident cancer in 3 countries and the most common cause of cancer deaths in 25 countries (eFigures 18 and 20 in the Supplement).

Between 2006 and 2016, TBL cancer cases increased by 28% (95% UI, 25%-32%) (Web Table 1; http://ghdx.healthdata.org/node/350478). Changing age structure contributed 19%, and population growth, 12%. A decrease in age-specific incidence partially offset this increase and would have led to a 3% decrease in incidence if age structure and population size had remained constant between 2006 and 2016 (eTable 14 and eFigure 21 in the Supplement). ASIRs between 1990 and 2016 show diverging results between men and women globally and in high and high-middle SDI countries, with the ASIR in men decreasing but increasing in women. In middle SDI countries, ASIRs increased for both men and women but remained stable in low-middle and low SDI countries (eFigures 23 and 24 in the Supplement).

2. Colon and Rectum Cancer
In 2016, there were 1.7 million (95% UI, 1.7-1.8 million) incident cases of colon and rectum cancer, and 830,000 (95% UI, 797,000-860,000) deaths (Table). Colon and rectum cancer caused 17.2 million (95% UI, 16.5-17.9 million) DALYs in 2016,
of which 97% came from YLLs and 3% from YLDs (eTable 15 and eFigure 4 in the Supplement). The odds of developing colon and rectum cancer globally was higher for men than for women (1 in 26 men, 1 in 41 women; eTable 16 in the Supplement). The highest odds were in the high SDI quintile (1 in 15 men, 1 in 24 women), and the lowest in the low SDI quintile (1 in 112 men, 1 in 116 women). Between 2006 and 2016, incidence increased by 34% (95% UI, 28%-41%), from 1.3 million (95% UI, 1.27-1.30 million) to 1.7 million (95% UI, 1.66-1.79 million) cases (eTable 14 in the Supplement). Most of this increase can be explained by an aging and growing population (19% and 12%, respectively); however, even with the same population size and age structure, colorectal cancer cases would have increased by 2% between 2006 and 2016 due to changing age-specific incidence rates. ASIRs between 1990 and 2016 were similar for men and women for all levels of SDI except for the high-middle SDI quintile, where trends leveled off in women but increased in men (eFigures 25 and 26 in the Supplement). Between 2006 and 2016, for both sexes combined, the ASIR and ASDR decreased in the high SDI quintile. In the high-middle, and middle SDI quintile, the ASDR decreased but the ASIR increased, and for low-middle, and low SDI countries, both ASIR and ASDR increased (eFigure 7 in the Supplement).

3. Breast Cancer

Breast cancer was the third most common incident cancer overall, with an estimated 1.7 million (95% UI, 1.6-1.8 million) incident cases in 2016. The vast majority occurred in women (1.68 million; 95% UI, 1.61-1.78 million) (Table). Breast cancer was among the top 3 leading causes of cancer in all SDI quintiles except for the high and middle SDI quintiles, where it was the fifth and fourth most common cancer, respectively (Figure 5). It caused 535 000 (95% UI, 506 000-573 000) deaths in women and 10 000 (95% UI, 7000-11 000) deaths in men, making it the fifth leading cause of cancer deaths for both sexes combined in 2016 globally (Figure 6). For women, breast cancer was the leading cause of cancer death in 2016 (Table). Breast cancer caused 15.1 million (95% UI, 14.3-16.2 million) DALYs for both sexes, of which 95% came from YLLs and 5% from YLDs (eTable 15 and eFigure 4 in the Supplement). Globally, 1 in 20 women developed breast cancer over a lifetime (eTable 16 in the Supplement). For women, the odds of developing breast cancer were the highest in high SDI countries (1 in 10), and the lowest in low SDI countries (1 in 50). For women, breast cancer was the most common cancer in 131 countries and the most common cause of cancer deaths in 112 countries (eFigures 18 and 20 in the Supplement). Overall incident cases increased by 29% because of a change in the population age struc-
ture (contributing 16%), population growth (contributing 12%), and an increase in age-specific incidence rates (contributing 1%) (eFigure 21 in the Supplement). Between 2006 and 2016, ASIRs decreased or remained stable in high, and high-middle SDI countries, but increased in the other SDI quintiles. ASDR decreased within that timeframe in all SDI quintiles, except for the low SDI quintile, where it increased (eFigure 8 in the Supplement).

4. Nonmelanoma Skin Cancer

In 2016, there were 1.5 million (95% UI, 1.1-2.0 million) incident cases of NMSC, of which 886,000 (95% UI, 574,000-1.3 million) were due to basal cell carcinoma (BCC) and 635,000 (95% UI, 386,000-922,000) due to squamous cell carcinoma (SCC). There were 53,000 (95% UI, 51,000-55,000) deaths due to NMSC (Table) and 1.0 million (95% UI, 981,000-1.1 million) DALYs, of which 97% came from YLLs and 3% from YLDs (eTable 15 and eFigure 4 in the Supplement). Over a lifetime, the odds of developing NMSC were 1 in 31 for men and 1 in 50 for women globally. For SCC in men, it ranged from 1 in 458 in low-middle SDI countries to 1 in 24 in high SDI countries; and for BCC, from 1 in 241 in low-middle SDI countries to 1 in 29 in high SDI countries (eTable 16 in the Supplement). An aging and growing population has led to a 12% (95% UI, 6%-19%) increase in NMSC cancer cases, from 1.4 million (95% UI, 999,000-1.8 million) in 2006-1.5 million (95% UI, 1.1-2.0 million) in 2016. The majority of this increase (20%) can be attributed to a change in the population age structure. Twelve percent can be attributed to population growth. Part of this increase was offset by a decrease in age-specific incidence rates between 2006 and 2016, which would have led to a 20% decrease in overall incidence of NMSC if the age structure and population size had remained stable during this timeframe (eTable 14 and eFigure 21 in the Supplement).

5. Prostate Cancer

In 2016, there were 1.4 million (95% UI, 1.3-1.6 million) incident cases of prostate cancer and 381,000 (95% UI, 321,000-413,000) deaths. Prostate cancer caused 6.1 million (95% UI, 5.0-6.6 million) DALYs globally in 2016, with 91% coming from YLLs and 9% from YLDs (eTable 15 and eFigure 4 in the Supplement). Globally, the odds of developing prostate cancer was 1 in 16 ranging from 1 in 56 for low-middle SDI countries to 1 in 7 in high SDI countries (eTable 16 in the Supplement). In 2016, prostate cancer was the cancer with the highest incidence for men in 92 countries, and the leading cause of cancer deaths for men in 48 countries (eFigures 17 and 19 in the Supplement). The increasing incidence rates, together with an aging and growing population, have led to a 40% increase in prostate cancer cases since 2006: 1.0 million (95% UI, 942,000-1.1 million) in 2006 to 1.4 million (95% UI, 1.3-1.6 million) in 2016. Twenty percent of this increase can be attributed to a
change in the population age structure, 12% to a change in the population size, and 7% to a change in the age-specific incidence rates (eTable 14 and eFigure 21 in the Supplement).

6. Stomach Cancer
In 2016, there were 1.2 million (95% UI, 1.1-1.2 million) incidence cases of stomach cancer and 834 000 (95% UI, 814 000-855 000) deaths worldwide. Stomach cancer caused 18.3 million (95% UI, 17.9-18.9 million) DALYs in 2016, with 98% coming from YLLs and 2% coming from YLDs (eTable 15 and eFigure 4 in the Supplement). One in 32 men and 1 in 80 women developed stomach cancer over a lifetime. The highest odds for men were in middle SDI countries (1 in 24), and the lowest in low SDI countries (1 in 90). For women, the highest odds were in high-middle SDI countries (1 in 69) and the lowest in low SDI countries (1 in 140) (eTable 16 in the Supplement). Between 2006 and 2016, stomach cancer moved from the second leading cause of crude cancer YLLs to the third place with a 4% decrease (~4% change; 95% UI, ~6.5% to ~1.5%) in absolute YLLs (Figure 7). Overall, incidence between 2006 and 2016 increased by 13%, of which a change in the population age structure contributed 18%; population growth, 12%; and falling age-specific rates, ~15%. (eTable 14 and eFigure 21 in the Supplement). ASIRs have dropped substantially since 1990 globally and for all SDI quintiles (eFigures 31 and 32 in the Supplement). ASIRs have dropped substantially since 1990 globally and for all SDI quintiles (eFigures 31 and 32 in the Supplement).

7. Liver Cancer
In 2016, there were 1.0 million (95% UI, 953 000-1.0 million) incidence cases of liver cancer globally and 829 000 (95% UI, 796 000-858 000) deaths. Liver cancer caused 21.1 million (95% UI, 20.3-22.0 million) DALYs in 2016, with 99% coming from YLLs and 1% coming from YLDs (eTable 15 and eFigure 4 in the Supplement). Globally, liver cancer was more common in men, with 1 in 38 men developing liver cancer compared with 1 in 111 women. The highest odds of developing liver cancer were in middle SDI countries (1 in 26 men, 1 in 76 women), whereas the lowest were seen in low-middle SDI countries (1 in 93 men, 1 in 195 women) (eTable 16 in the Supplement). Population aging and population growth were the drivers of the increase from 732 000 (95% UI, 702 000-747 000) cases in 2006 to 1.0 million (95% UI, 953 000-1.0 million) cases in 2016 (eTable 14 and eFigure 21 in the Supplement). Of the 38% increase in cases between 2006 and 2016, 16% was due to population aging, 12% due to population growth, and 9% due to an increase in age-specific incidence rates. Trends in ASIRs for liver cancer differ by SDI quintile. For women, rates decreased in the middle, low-middle, and low SDI quintiles, whereas they increased in the high SDI quintile (eFigure 33 in the Supplement). The same increase in the high SDI quintile can be seen in men (eFigure 34 in the Supplement). Between 2006 and 2016, ASIRs for both sexes increased in the high, high-middle, and middle SDI countries but decreased in the...
Figure 5. Cancers Ranked by Number of Incident Cases in Both Sexes, Globally, by Sociodemographic Index Status, 1990 to 2016

| Region                          | 1990 | 2000 | 2010 | 2016 |
|---------------------------------|------|------|------|------|
| North Africa and Middle East    |      |      |      |      |
| Central Sub-Saharan Africa      |      |      |      |      |
| Central Latin America           |      |      |      |      |
| Eastern Europe                  |      |      |      |      |
| Saudi Arabia                    |      |      |      |      |
| South Korea                     |      |      |      |      |
| Afghanistan                     |      |      |      |      |
| Australasia                     |      |      |      |      |
| Venezuela                       |      |      |      |      |
| Caribbean                       |      |      |      |      |
| Germany                         |      |      |      |      |
| East Asia                       |      |      |      |      |
| Tanzania                        |      |      |      |      |
| Oceania                         |      |      |      |      |
| Canada                          |      |      |      |      |
| Mexico                          |      |      |      |      |
| Russia                          |      |      |      |      |
| China                           |      |      |      |      |
| Iraq                            |      |      |      |      |
| North Africa and Middle East    |      |      |      |      |
| Central Sub-Saharan Africa      |      |      |      |      |
| Central Latin America           |      |      |      |      |
| Eastern Europe                  |      |      |      |      |
| Saudi Arabia                    |      |      |      |      |
| South Korea                     |      |      |      |      |
| Afghanistan                     |      |      |      |      |
| Australasia                     |      |      |      |      |
| Venezuela                       |      |      |      |      |
| Caribbean                       |      |      |      |      |
| Germany                         |      |      |      |      |
| East Asia                       |      |      |      |      |
| Tanzania                        |      |      |      |      |
| Oceania                         |      |      |      |      |
| Canada                          |      |      |      |      |
| Mexico                          |      |      |      |      |
| Russia                          |      |      |      |      |
| China                           |      |      |      |      |
| Iraq                            |      |      |      |      |

Note: The table above represents the ranking of cancers based on the number of incident cases globally from 1990 to 2016, categorized by sociodemographic index (SDI) status. The data is color-coded to indicate relative rankings across different regions and time periods.
Figure 6. Cancers Ranked by Number of Deaths in Both Sexes, Globally, by Sociodemographic Index Status, and in the 50 Most Populous Countries, 2016
low-middle, and low SDI countries. The ASDRs during that time-frame decreased in all SDI quintiles except for the low SDI quintile, where it increased by 3% (eFigure 11 in the Supplement).

8. Cervical Cancer
In 2016, 511,000 (95% UI, 414,000-542,000) women developed cervical cancer worldwide, and it caused 247,000 (95% UI, 204,000-263,000) deaths (Table). Cervical cancer caused 7.4 million (95% UI, 6.0-7.9 million) DALYs, with 97% coming from YLLs and 3% from YLDs (eTable 15 and eFigure 4 in the Supplement). Globally, 1 in 75 women developed cervical cancer during a lifetime (eTable 16 in the Supplement). The odds were the highest in low SDI countries (1 in 31), and the lowest in high SDI countries (1 in 117). Cervical cancer was the most common cause for cancer incidence and death in low SDI countries (Web Table 4; http://ghdx.healthdata.org/node/350478). In 2016, cervical cancer was the most common incident cancer for women in 51 countries (eFigure 18 in the Supplement) and the most common cause of cancer deaths in 42 countries (eFigure 20 in the Supplement). Between 2006 and 2016, incident cases increased by 9% (95% UI, 2%-17%) globally. Population growth contributed 12%, and population aging, 11%, while falling age-specific incidence rates offset this increase by ~15% (eFigure 21 and eTable 14 in the Supplement). Deaths increased by 7% (95% UI, 1%-15%) between 2006 and 2016, and DALYs by 5% (95% UI, −1% to 13%) (Web Table 1; http://ghdx.healthdata.org/node/350478). ASIRs decreased globally, and for all SDI quintiles (eFigure 35 in the Supplement).

9. Leukemia
In 2016, there were 467,000 (95% UI, 423,000-499,000) new cases of leukemia worldwide and 310,000 (95% UI, 286,000-324,000) deaths. In 2016, leukemia caused 10.2 million (95% UI, 9.3-10.8 million) DALYs globally, with 98% coming from YLLs and 2% from YLDs (eTable 15 and eFigure 4 in the Supplement). Globally, 1 in 188 men compared with 1 in 194 women developed leukemia. Between 2006 and 2016, incident cases
increased by 26% from 370,000 (95% UI, 344,000-385,000) to 467,000 (95% UI, 423,000-489,000). The main contributors to this increase were population growth with 12%, population aging with 10%, and an increase in age-specific incidence rates with 3% (eFigure 21 and eTable 14 in the Supplement). ASIR trends between 1990 and 2016 for women showed decreasing trends in the low-middle SDI and low SDI quintiles but increasing trends over the last decade in high-middle and middle SDI quintiles (eFigure 36 in the Supplement). For men, rates remained stable between 1990 and 2016 in middle, low-middle, and low SDI countries but increased in high SDI and high-middle SDI countries (eFigure 37 in the Supplement).

10. Non-Hodgkin Lymphoma
In 2016, there were 461,000 (95% UI, 428,000-482,000) incident cases of non-Hodgkin lymphoma and 240,000 (95% UI, 221,000-248,000) deaths. Non-Hodgkin lymphoma caused 6.8 million (95% UI, 6.2-7.1 million) DALYs in 2016, with 98% coming from YLLs and 2% from YLDs (eTable 15 and eFigure 4 in the Supplement). Globally, 1 in 110 men and 1 in 161 women developed non-Hodgkin lymphoma over a lifetime. The highest odds were in high SDI countries (1 in 48 for men, 1 in 70 for women), and the lowest were in low-middle SDI countries (1 in 274 for men, 1 in 401 for women) (eTable 16 in the Supplement). Globally, incident cases between 2006 and 2016 increased by 45% (95% UI, 38%-48%), of which 17% was due to increasing age-specific incidence rates, 15% to changing population age structure, and 12% to population growth (eTable 14 and eFigure 21 in the Supplement). In eFigures 38 and 39 in the Supplement, the slight increase in ASIRs between 1990 and 2016 is shown, with very similar trends for men and women and all SDI quintiles except for the high SDI quintile, where ASIRs increase more rapidly.

Trends in Incidence for Less Common Cancers
Globally, incident cases for all cancers increased significantly between 2006 and 2016 for both sexes combined. Of the cancers other than the top 10, the top 3 cancers with the largest increase in incident cases were thyroid cancer (50% increase; 95% UI, 43%-59%); uterine cancer (40% increase; 95% UI, 34%-50%); and melanoma (39% increase; 95% UI, 33%-43%) (Web Table 1; http://ghdx.healthdata.org/node/350478). For thyroid cancer, of the 50% increase, 25% can be explained by rising age-specific incidence rates, 12% by an increase in population size, and 12% by a change in age structure. For uterine cancer, of the 40% increase, 18% was due to a change in the population age structure, 12% to an increase in population size, and 10% to a rise in age-specific incidence rates. For melanoma, of the 39% increase, 15% was due to a change in the population age structure, 12% to population growth, and 11% to a change in age-specific incidence rates (eTable 14 in the Supplement).

Discussion
We updated our previous reports and analyzed cancer registry, vital registration, and verbal autopsy data to estimate the burden of cancer for 195 countries and territories from 1990 to 2016.2,15 In this article, we focus on the changes over the last decade (2006-2016). All results presented can also be found online at https://vizhub.healthdata.org/gbd-compare/. Changes compared with our previous reports include the addition of NMSC, additional data sources (eTable 3 in the Supplement), and improvements in the estimation of the MIR.

We found that the global cancer burden between 2006 and 2016 increased in terms of incident cases, deaths, and DALYs, with vast heterogeneity by cancer type, location, and sex. A large proportion of the increase in cancer incidence can be explained by improving life expectancy and population growth—a development that can at least partially be attributed to a reduced burden from other common diseases.8,14 However, the contribution of population aging vs population growth to changes in incident cases differs substantially based on socioeconomic development. This leads to very different compositions of cancer types contributing to total incident cases in a population depending on the age structure.

Despite the rapidly increasing cancer burden in lower SDI countries, the odds of developing cancer and age-standardized rates are still higher in countries of higher SDI. Notable exceptions are cancers with infectious etiologies like cervical, liver, and stomach cancer.

Infectious Causes for Cancer
Cervical cancer is the most striking example of inequity for cancers of infectious etiologies, where women in low SDI countries are almost 4 times more likely to develop cervical cancer compared with women in high SDI countries, and where cervical cancer is the most common cause of cancer incidence and deaths. A positive development is that cervical cancer ASIRs have fallen in all SDI quintiles, likely due to improvements in primary and secondary prevention as well as improvements in SDI.16 However, with almost a quarter million women still dying annually from a preventable cancer, much work is left to be done.17

Stomach and liver cancer are another example of the large heterogeneity in the burden of cancers with infectious etiologies. As is the case with cervical cancer, a positive development is that stomach cancer rates have fallen in all SDI quintiles over the last decade. Liver cancer is the leading cause of cancer deaths in many lower SDI countries but only the seventh leading cause of cancer deaths in high SDI countries. A concerning trend, however, is that rates in higher SDI countries are increasing, which has been attributed to increasing risk factors like nonalcoholic steatohepatitis, alcohol abuse, and hepatitis B and C in certain populations.18-20

Potential for Cancer Prevention
The mostly positive development for cancers with an infectious etiology can at least partially be attributed to the large prevention potential. Common cancers without infectious etiologies but also with a large prevention potential include TBL cancers through tobacco control; colorectal cancer through screening, dietary interventions, and the promotion of physical activity; and skin cancer through prevention of excessive UV exposure. For TBL cancer, ASIRs in higher SDI countries
have decreased over the last decade, which can be attributed to tobacco control. However, even though TBL cancer rates in lower SDI countries are below the rates in higher SDI countries, ASIRs in lower SDI countries increased between 2006 and 2016. This highlights the importance of focusing tobacco control efforts on lower SDI countries, to avoid these countries’ having to experience the same tragedy of unnecessary tobacco-related deaths that many high SDI countries have had to face. In addition to tobacco control, indoor and outdoor air pollution have to be considered as important risk factors for lung cancer in certain locations. When considering the value of prevention strategies, the benefit in reducing diseases other than cancer can be considerable, as is the case for example with tobacco control.

Unfortunately, cancer prevention efforts are less effective for common cancers like breast and prostate cancer, as well as hematological malignant conditions like leukemia and non-Hodgkin lymphoma, and pediatric cancers. Also, cancer prevention always has to be seen in conjunction with expanding access to early detection and treatment to not neglect co-horts of current or future patients for whom cancer prevention efforts come too late.

**Need for Access to Cancer Care**

Since even in the best-case scenario only a fraction of cancers are preventable under current conditions, providing universal access to health care is crucial for cancer control. Especially the finding of increasing ASIRs for some cancers at the same time as ASDRs are decreasing in higher SDI countries, which points to the benefits of early cancer detection and effective treatment but also highlights the potential for overdiagnosis.

Globally, most of the cancer burden still comes from YLLs rather than YLDs, reflecting a higher burden of deaths than disability. However, as cancer treatment improves and the population ages, survivorship care becomes an essential part of the cancer continuum. Over the last decade, resource-stratified guidelines that encompass this continuum from diagnosis through survivorship to end-of-life care have been developed. Together with the GBD estimates and other data on the local burden of cancer, these guidelines provide countries helpful tools when designing health policies and cancer control plans.

**Limitations**

For effective cancer control and resource allocation, information on the local cancer burden but also on the burden of other diseases is crucial. The GBD estimates fill a gap where actual data on disease burden are sparse or unavailable. However, in these cases, estimates have wide uncertainty, and it remains crucial to improve data collection through the expansion and creation of vital registration systems, cancer registries, health surveys, and other data systems. Differences in data collection practices and coding systems, as well as quality of data sources, remain major challenges, as do underreporting of cancers requiring advanced diagnostics in low-resource settings (e.g., brain cancer, leukemias, and others). Cancers that are common in the pediatric population but rare in adults are aggregated to an “other neoplasm” group, encompassing about 30% of the pediatric cancer burden and making these estimates less valuable for cancer control.

**Conclusions**

With the annual updates of the GBD cancer estimates, our goal is to provide relevant and current information on the global, regional, and national burden of cancer. The GBD 2016 study offers new insights into the magnitude of cancer disparities. With population aging and the epidemiological transition, cancer incidence will increase in the future, further widening the cancer divide if current trends continue. The data showing the disparities and knowledge on the root causes exist, as do the tools to reduce them. However, strategic investments in cancer control and implementation of effective programs to ensure universal access to cancer care are required to achieve the Sustainable Development Goals as well as targets set in the WHO Global Action Plan on NCDs.
Contributors: Dr Fitzmaurice had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Dr Postma, Drs Murray and Naghavi.

Obtaining funding: Murray, Dr Postma, Drs Murray and Naghavi.

Statistical analysis: Drs Postma and Murray.

Tables and figures: Murray, Drs Postma and Murray.

Writing the manuscript: Murray, Dr Postma, Drs Murray and Naghavi.

Critical review of the manuscript for important intellectual content: All authors.

Financial activities outside the submitted work: All authors.

Funding/Support: The Institute for Health Metrics and Evaluation received funding from the Bill & Melinda Gates Foundation.

Research Center, Mazandaran University of Medical Sciences, Sari, Iran (Moosazadeh); Lancaster Medical School, Lancaster University, Lancaster, England (Morga); Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran (Mousavi); Suraya Ege Institute, Nagpur, Maharashtra, India (Nangia); Institute for Global Health Innovations, Duy Tan University, Da Nang, Vietnam (Nguyen, N. T. T. Tran); Centre for Health Research, Western Sydney University, Sydney, New South Wales, Australia (Ogbo); Department of Psychiatry, College of Medicine, University of Lagos, Lagos, Lagos State, Nigeria (Olagunju); Department of Psychiatry, Lagos University Teaching Hospital, Lagos, Nigeria (Olagunju); Discipline of Psychiatry, University of Adelaide, Adelaide, South Australia, Australia (Ogbo); Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Kraków, Poland (Topor-Madry); Faculty of Health Sciences, Wroclaw Medical University, Wroclaw, Poland (Topor-Madry); Johns Hopkins University, Baltimore, Maryland (B. X. Tran); Hanoi Medical University, Hanoi, Vietnam (B. X. Tran); Department of Internal Medicine, Federal Teaching Hospital, Abakaliki, Ebonyi State, Nigeria (Ukwaja); National Research University Higher School of Economics, Moscow, Russia (Vlassov); Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway (Weiderpass); Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway (Weiderpass); Genetic Epidemiology Group, Folkhalsan Research Center, Helsinki, Finland (Weiderpass); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Weiderpass); Centre of Evidence-Based Dermatology, University of Nottingham, Nottingham, England (Williams); Woldia University, Woldia, Amhara, Ethiopia (Yimer); Department of Biostatistics, School of Public Health, Kyoto University, Kyoto, Japan (Yonemoto); Jackson State University, Jackson, Mississippi (Younis).

Competing Interests: Dr Postma reports financial activities outside the submitted work and has received grants and honoraria from Astra Zeneca, Roche, Eli Lilly, Abbott, Sanofi, MSD, Glaxo Smith Kline, and Merck & Co, Inc.

Funding/Support: The Institute for Health Metrics and Evaluation received funding from the Bill & Melinda Gates Foundation.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; data collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication design, data collection, data analysis, data interpretation, or writing of this paper.

Meeting Presentation: This article was presented at the American Society of Clinical Oncology (ASCO) 2018 Meeting; June 2, 2018; Chicago, Illinois.

REFERENCES

1. Seventieth World Health Assembly. Cancer prevention and control in the context of an integrated approach. http://apps.who.int/gb/ebwha/pdf_files/WHA70/A70_R12-en.pdf. Accessed May 15, 2018.

2. United Nations. 2011 High Level Meeting on Prevention and Control of Non-Communicable Diseases. http://www.un.org/en/ga/ncdmeeting2011/. Accessed May 15, 2018.

3. World Health Organization. Global Action Plan for the Prevention and Control of NCDs 2013-2020. http://www.who.int/nmh/events/ncd_action_plan/en/. Accessed May 15, 2018.

4. United Nations. Sustainable Development Goals. Published January 2016. https://sustainabledevelopment.un.org/. Accessed September 1, 2016.

5. GBD 2016 SDG Collaborators. Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1423-1459. doi:10.1016/S0140-6736(17)32336-X

6. Horton R. Offline: NCDs—why are we failing? Lancet. 2017;390(10092):346. doi:10.1016/S0140-6736(17)31919-0

7. Fitzmaurice C, Allen C, Barber RM, et al. Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524-546. doi:10.1001/jamaoncol.2016.5688

8. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151-1210. doi:10.1016/S0140-6736(17)32152-9

9. GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1260-1344. doi:10.1016/S0140-6736(17)32130-X

10. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211-1259. doi:10.1016/S0140-6736(17)32154-2

11. GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1345-1422. doi:10.1016/S0140-6736(17)32366-8

12. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-171. doi:10.1016/S0140-6736(14)61682-2

13. Foreman KJ, Lozano R, Lopez AD, Murray CJ. Modeling causes of death: an integrated approach using CODEm. Popul Health Metr. 2012;10:1. doi:10.1186/1478-7954-10-1

14. GBD 2016 Mortality Collaborators. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1084-1150. doi:10.1016/S0140-6736(17)31813-0

15. Fitzmaurice C, Dicker D, Pain A, et al. Global Burden of Disease Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3(12):1683-1691. doi:10.1001/jamaoncol.2017.3055

16. Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer. 2013;49(15):3262-3273. doi:10.1016/j.ejca.2013.04.024

17. Tsu V, Jerónimo J. Saving the world's women from cervical cancer. N Engl J Med. 2016;374(26):2509-2511. doi:10.1056/NEJMmp1604113

18. Ryerson AB, Ehemann CR, Altekruse SF, et al. Annual report to the nation on the status of cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122(9):1312-1337. doi:10.1002/cncr.29936

19. Akinremi-Otike O, Akeri S, Ahmed M, et al. Global Burden of Liver Disease Liver Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3(12):1683-1691. doi:10.1001/jamaoncol.2017.3055

20. Pauw D, Rota M, Rehm J, et al. Cancer incidence and mortality attributable to alcohol consumption. Int J Cancer. 2016;138(6):1380-1387. doi:10.1002/ijc.29890

21. Jha P, Petru R. Global effects of smoking, of quitting, and of taxing tobacco. N Engl J Med. 2014;370(1):60-68. doi:10.1056/NEJMp1308383

22. Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid-cancer epidemic? the increasing impact of overdiagnosis. N Engl J Med. 2016;375(7):614-617. doi:10.1056/NEJMmp1604412

23. Anderson BO, Duggan C. Resource-stratified guidelines for cancer management: correction and commentary. J Glob Oncol. 2016;2(1):84-88. doi:10.1200/JGO.2016.00213